Zura Bio (NASDAQ:ZURA) Stock Price Up 5.6% – Here’s Why

Zura Bio Limited (NASDAQ:ZURA)’s stock price traded up 5.6% during trading on Wednesday . The stock traded as high as $5.46 and last traded at $5.3640. 121,596 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 843,188 shares. The stock had previously closed at $5.08.

Analyst Upgrades and Downgrades

ZURA has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Monday. Oppenheimer lowered their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th. Wedbush reaffirmed an “outperform” rating and set a $15.00 target price on shares of Zura Bio in a research note on Wednesday, July 1st. William Blair assumed coverage on Zura Bio in a research report on Wednesday. They set an “outperform” rating for the company. Finally, Chardan Capital increased their price target on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Price Performance

The firm has a market capitalization of $489.58 million, a P/E ratio of -4.75 and a beta of -0.03. The firm’s fifty day moving average price is $4.44 and its 200-day moving average price is $5.32.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Analysts expect that Zura Bio Limited will post -0.76 earnings per share for the current year.

Institutional Trading of Zura Bio

Several institutional investors have recently modified their holdings of the company. Suvretta Capital Management LLC boosted its stake in Zura Bio by 1.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after buying an additional 94,110 shares in the last quarter. VR Adviser LLC raised its position in Zura Bio by 15.4% in the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after acquiring an additional 713,899 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Zura Bio by 78.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares during the last quarter. Siren L.L.C. lifted its holdings in Zura Bio by 187.3% in the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock valued at $22,222,000 after acquiring an additional 2,434,866 shares during the last quarter. Finally, Commodore Capital LP bought a new position in shares of Zura Bio during the 1st quarter valued at about $19,338,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.